Thursday, January 17, 2013

Partnerships Session Spotlight: Adapting Strategic Partnerships to the Needs of Emerging Markets

Between regulatory concerns, on-the-ground logistics, patient recruitment and everything in between, running trials in emerging regions has ups and downs in the scheme of drug development. Over the last several years clinical development has seen the rise in strategic partnerships between sponsors and their suppliers as well as the drive to expand research in emerging markets. These two trends have coalesced and created a robust set of lessons learned on what sponsors and CROs can do to maximize their relationships in emerging regions.

Global Clinical Session
This week's featured Partnerships in Clinical Trials session addresses all these things and more. For more about the session Adapting Strategic Partnerships to the Needs of Emerging Markets is featured in the Optimize Current Outsourcing Models track. For more information on this track and the rest of the program,download the brochure. If you'd like to join us in Orlando, as a reader of this blog, when you register to join us and mention code XP1800BLOG to save 15% off the standard rate.

Featured Session: Adapting Strategic Partnerships to the Needs of Emerging Markets

Featured Speakers: Octavio Costa, MD, Executive Director, EM Clinical Development Operations, Merck & Co., Inc.
Christopher Erickson, Vice President, Strategic Account Leader, PAREXEL International Corporation

About the session: Over the last several years clinical development has seen the rise in strategic partnerships between sponsors and their suppliers as well as the drive to expand research in emerging markets. These two trends have coalesced and created a robust set of lessons learned on what sponsors and CROs can do to maximize their relationships in emerging regions. Several critical areas have been identified to the success of a partnership centered on emerging regions. This session explores best practices through the use of various case studies.

  • • Understand the key differences of conducting clinical trials in emerging markets
  • • Techniques to maximize strategic partnerships in emerging regions including identifying and prioritizing the partnership infrastructure and adapting key areas of governance




No comments: